<DOC>
	<DOCNO>NCT02528838</DOCNO>
	<brief_summary>The study design prospective , non-interventional , observational single arm study . Hundred-fifty patient 18 stable disease least partial response treatment lenalidomide recruit approximately 20 haematology/oncology site Netherlands . Recruitment continue 150 patient start study . When target reach , patient lenalidomide continue follow last patient follow 36 month .</brief_summary>
	<brief_title>An Observational Study Assess Safety Outcome Various Medication Usage Patterns Clinical Routine Practice Patients Receiving Lenalidomide .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>Patients 18 year age understand voluntarily sign informed consent form . Patients multiple myeloma currently receive lenalidomide treatment take lenalidomide &gt; 2 cycle &lt; 6 cycle . Patients currently stable disease meeting criterion complete response , good partial response partial response lenalidomide treatment . Refusal participate study . Women pregnant breastfeeding . Women childbearing potential unless condition Pregnancy Prevention Programme meet . Hypersensitivity active substance excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Non-interventional</keyword>
	<keyword>Observational</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>REVIEW</keyword>
	<keyword>Post-authorization</keyword>
	<keyword>Netherlands</keyword>
</DOC>